Skip to content

Julia Kuder

Oslo University Hospital

2 papers in the Anchorcite directory, published between 2017 and 2018, cited 12,957 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations

    BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…

  2. Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine · 2017 · 6,357 citations

    BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving…

Metadata from OpenAlex (CC0).